Literature DB >> 25485963

μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.

Marino Convertino1, Alexander Samoshkin2, Josee Gauthier3, Michael S Gold4, William Maixner5, Nikolay V Dokholyan6, Luda Diatchenko7.   

Abstract

The μ-opioid receptor (MOR) is the primary target for opioid analgesics. MOR induces analgesia through the inhibition of second messenger pathways and the modulation of ion channels activity. Nevertheless, cellular excitation has also been demonstrated, and proposed to mediate reduction of therapeutic efficacy and opioid-induced hyperalgesia upon prolonged exposure to opioids. In this mini-perspective, we review the recently identified, functional MOR isoform subclass, which consists of six transmembrane helices (6 TM) and may play an important role in MOR signaling. There is evidence that 6 TM MOR signals through very different cellular pathways and may mediate excitatory cellular effects rather than the classic inhibitory effects produced by the stimulation of the major (7 TM) isoform. Therefore, the development of 6 TM and 7 TM MOR selective compounds represents a new and exciting opportunity to better understand the mechanisms of action and the pharmacodynamic properties of a new class of opioids.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6TM MOR isoform; Drug discovery; Review; μ-Opioid receptor

Mesh:

Substances:

Year:  2014        PMID: 25485963      PMCID: PMC4646084          DOI: 10.1016/j.pnpbp.2014.11.009

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  62 in total

Review 1.  Cellular and synaptic adaptations mediating opioid dependence.

Authors:  J T Williams; M J Christie; O Manzoni
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

2.  The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors.

Authors:  K D Karpa; R Lin; N Kabbani; R Levenson
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

Review 3.  Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors.

Authors:  Emmanuel Hermans
Journal:  Pharmacol Ther       Date:  2003-07       Impact factor: 12.310

Review 4.  Opioid tolerance and hyperalgesia.

Authors:  Grace Chang; Lucy Chen; Jianren Mao
Journal:  Med Clin North Am       Date:  2007-03       Impact factor: 5.456

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 6.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

Review 7.  Opioids and their receptors: Are we there yet?

Authors:  Gavril W Pasternak
Journal:  Neuropharmacology       Date:  2013-04-26       Impact factor: 5.250

8.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

9.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

10.  The roles played by highly truncated splice variants of G protein-coupled receptors.

Authors:  Helen Wise
Journal:  J Mol Signal       Date:  2012-09-01
View more
  7 in total

Review 1.  Brain circuits for pain and its treatment.

Authors:  Nicole Mercer Lindsay; Chong Chen; Gadi Gilam; Sean Mackey; Grégory Scherrer
Journal:  Sci Transl Med       Date:  2021-11-10       Impact factor: 17.956

Review 2.  Pain and Poppies: The Good, the Bad, and the Ugly of Opioid Analgesics.

Authors:  Tuan Trang; Ream Al-Hasani; Daniela Salvemini; Michael W Salter; Howard Gutstein; Catherine M Cahill
Journal:  J Neurosci       Date:  2015-10-14       Impact factor: 6.167

3.  Structural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signaling.

Authors:  Alexander Samoshkin; Marino Convertino; Chi T Viet; Jeffrey S Wieskopf; Oleg Kambur; Jaclyn Marcovitz; Pinkal Patel; Laura S Stone; Eija Kalso; Jeffrey S Mogil; Brian L Schmidt; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

4.  Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide.

Authors:  Laurie-Anne Roeckel; Valérie Utard; David Reiss; Jinane Mouheiche; Hervé Maurin; Anne Robé; Emilie Audouard; John N Wood; Yannick Goumon; Frédéric Simonin; Claire Gaveriaux-Ruff
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

5.  Effect of catechol-O-methyltransferase (rs4680) single-nucleotide polymorphism on opioid-induced hyperalgesia in adults with chronic pain.

Authors:  W Michael Hooten; Danqing Hu; Julie M Cunningham; John L Black
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

6.  Differential Regulation of 6- and 7-Transmembrane Helix Variants of μ-Opioid Receptor in Response to Morphine Stimulation.

Authors:  Marino Convertino; Alexander Samoshkin; Chi T Viet; Josee Gauthier; Steven P Li Fraine; Reza Sharif-Naeini; Brian L Schmidt; William Maixner; Luda Diatchenko; Nikolay V Dokholyan
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

7.  Alternative Splicing of Opioid Receptor Genes Shows a Conserved Pattern for 6TM Receptor Variants.

Authors:  Marjo Piltonen; Andrey Krokhotin; Marc Parisien; Pierre Bérubé; Haig Djambazian; Rob Sladek; Nikolay V Dokholyan; Svetlana A Shabalina; Luda Diatchenko
Journal:  Cell Mol Neurobiol       Date:  2020-10-03       Impact factor: 5.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.